Adicet Bio (ACET) Research & Development (2017 - 2026)
Adicet Bio (ACET) posted quarterly Research & Development of $17.5 million for Q1 2026, down 23.35% year-over-year from $22.8 million in Q1 2025, and down 30.15% quarter-over-quarter from $25.0 million in Q4 2025.
Adicet Bio (ACET) Research & Development (2017 - 2026) Analysis & Trends
Adicet Bio's Research & Development history runs 10 years deep, the most recent figure standing at $17.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 23.35% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $93.8 million (down 4.52% YoY), while the FY2025 annual figure was $99.1 million, changed 0.2% from the prior year.
- Research & Development for Q1 2026 stood at $17.5 million, down from $25.0 million in the prior quarter.
- The five-year high for Research & Development was $28.4 million in Q2 2025, with the low at $13.5 million in Q1 2022.
- The 5-year median for Research & Development is $24.8 million (2023), against an average of $23.1 million.
- The sharpest annual moves came in 2023 and 2026: Research & Development soared 98.44% in 2023, then slipped 23.35% in 2026.
- Adicet Bio's Research & Development stood at $25.0 million in 2022, then declined by 1.02% to $24.8 million in 2023, then slipped by 6.0% to $23.3 million in 2024, then grew by 7.58% to $25.0 million in 2025, then sank by 30.15% to $17.5 million in 2026.
- Business Quant data shows ACET's Research & Development at $17.5 million in Q1 2026, $25.0 million in Q4 2025, and $22.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 97.90 Mn |
| 10 | Adicet Bio | 99.93 Mn | -18.26 Mn | - | 18.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.45 Mn |
| Mar 31, 2026 | 17.49 Mn |
| Dec 31, 2025 | 25.04 Mn |
| Sep 30, 2025 | 22.85 Mn |
| Jun 30, 2025 | 28.42 Mn |
| Mar 31, 2025 | 22.81 Mn |
| Dec 31, 2024 | 23.27 Mn |
| Sep 30, 2024 | 26.25 Mn |
| Jun 30, 2024 | 25.90 Mn |
| Mar 31, 2024 | 23.90 Mn |
| Dec 31, 2023 | 24.76 Mn |
| Sep 30, 2023 | 26.17 Mn |
| Jun 30, 2023 | 28.36 Mn |
| Mar 31, 2023 | 26.76 Mn |
| Dec 31, 2022 | 25.02 Mn |
| Sep 30, 2022 | 16.57 Mn |
| Jun 30, 2022 | 16.18 Mn |
| Mar 31, 2022 | 13.48 Mn |
| Dec 31, 2021 | 14.66 Mn |
| Sep 30, 2021 | 11.93 Mn |